DE2360796B2 - Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm - Google Patents
Arzneimittel mit verzoegerter abgabe des wirkstoffs im darmInfo
- Publication number
- DE2360796B2 DE2360796B2 DE19732360796 DE2360796A DE2360796B2 DE 2360796 B2 DE2360796 B2 DE 2360796B2 DE 19732360796 DE19732360796 DE 19732360796 DE 2360796 A DE2360796 A DE 2360796A DE 2360796 B2 DE2360796 B2 DE 2360796B2
- Authority
- DE
- Germany
- Prior art keywords
- release
- parts
- intestine
- drug
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000000936 intestine Anatomy 0.000 title claims description 6
- 230000003111 delayed effect Effects 0.000 title claims description 4
- 239000013543 active substance Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 22
- 159000000007 calcium salts Chemical class 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- -1 fatty acid triglycerides Chemical class 0.000 claims description 3
- 239000002245 particle Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 19
- 239000008188 pellet Substances 0.000 description 18
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 16
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristoyl-sn-glycerol Natural products CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 13
- FVVDKUPCWXUVNP-UHFFFAOYSA-M Aminosalicylate sodium anhydrous Chemical compound [Na+].NC1=CC=C(C([O-])=O)C(O)=C1 FVVDKUPCWXUVNP-UHFFFAOYSA-M 0.000 description 10
- 125000005456 glyceride group Chemical group 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000007711 solidification Methods 0.000 description 5
- 230000008023 solidification Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229940078480 calcium levulinate Drugs 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012907 medicinal substance Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 229960003223 tripelennamine Drugs 0.000 description 2
- FSSICIQKZGUEAE-UHFFFAOYSA-N 2-[benzyl(pyridin-2-yl)amino]ethyl-dimethylazanium;chloride Chemical compound Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 FSSICIQKZGUEAE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 244000151018 Maranta arundinacea Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000404546 Soliva Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940113164 trimyristin Drugs 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19732360796 DE2360796B2 (de) | 1973-12-06 | 1973-12-06 | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
| AR253732A AR204629A1 (es) | 1973-12-06 | 1974-01-01 | Procedimiento para la elaboracion de medicamentos con cesion retardada de la sustancia activa en el intestino |
| BE141040A BE811175A (fr) | 1973-12-06 | 1974-02-18 | Produit pharmaceutique a liberation retardee dans l'intestin de l'agent actif |
| ES423856A ES423856A1 (es) | 1973-12-06 | 1974-03-04 | Procedimiento para la elaboracion de medicamentos con ce- sion retardada de la sustancia activa en el instestino. |
| GB1148774A GB1427677A (en) | 1973-12-06 | 1974-03-14 | Delayed release pharmaceutical preparation and a method of producing the same |
| FR7413730A FR2253508B1 (OSRAM) | 1973-12-06 | 1974-04-19 | |
| NL7407233A NL7407233A (nl) | 1973-12-06 | 1974-05-29 | Werkwijze ter bereiding van een geneesmiddel met vertraagde afgifte van de aktieve stof in het darmkanaal. |
| DK303974A DK137310C (da) | 1973-12-06 | 1974-06-06 | Fremgangsmaade til fremstilling af fedtsyretriglyceridindkapslede laegemidler med forsinket afgivelse af virksomt stof i tarmen |
| SE7407537A SE7407537L (OSRAM) | 1973-12-06 | 1974-06-07 | |
| JP49098842A JPS5089521A (OSRAM) | 1973-12-06 | 1974-08-28 | |
| US05/511,174 US4013784A (en) | 1973-12-06 | 1974-10-02 | Delayed release pharmaceutical preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19732360796 DE2360796B2 (de) | 1973-12-06 | 1973-12-06 | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2360796A1 DE2360796A1 (de) | 1975-06-12 |
| DE2360796B2 true DE2360796B2 (de) | 1977-06-02 |
Family
ID=5900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732360796 Ceased DE2360796B2 (de) | 1973-12-06 | 1973-12-06 | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4013784A (OSRAM) |
| JP (1) | JPS5089521A (OSRAM) |
| AR (1) | AR204629A1 (OSRAM) |
| BE (1) | BE811175A (OSRAM) |
| DE (1) | DE2360796B2 (OSRAM) |
| DK (1) | DK137310C (OSRAM) |
| ES (1) | ES423856A1 (OSRAM) |
| FR (1) | FR2253508B1 (OSRAM) |
| GB (1) | GB1427677A (OSRAM) |
| NL (1) | NL7407233A (OSRAM) |
| SE (1) | SE7407537L (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013106998A1 (de) * | 2013-07-03 | 2015-01-08 | Thyssenkrupp Industrial Solutions Ag | Verfahren sowie eine Vorrichtung zur Herstellung einer Tablette |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691181A (en) * | 1984-08-21 | 1997-11-25 | Celltech Limited | DNA encoding lipase from human gastric mucosal tissue |
| US4755387A (en) * | 1985-03-21 | 1988-07-05 | The Procter & Gamble Company | Therapeutic particles |
| US5112619A (en) * | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
| NL8701335A (nl) * | 1986-06-21 | 1988-01-18 | Sandoz Ag | Orale farmaceutische preparaten. |
| EP0345628B1 (en) * | 1988-06-07 | 1993-05-12 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
| US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
| DE3833448A1 (de) * | 1988-10-01 | 1990-04-12 | Hoechst Ag | Verfahren zur gewinnung von ibuprofen fuer die direkttablettierung |
| EP0366058A3 (en) * | 1988-10-27 | 1991-03-20 | Abbott Laboratories | Controlled-release delivery device, method for producing device, and method of using device |
| GB8904182D0 (en) * | 1989-02-23 | 1989-04-05 | Glaxo Canada | Pharmaceutical compositions |
| SE9003296L (sv) * | 1990-10-16 | 1992-04-17 | Kabi Pharmacia Ab | Foerfarande foer att formulera laekemedel |
| SE9200858L (sv) * | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Metod för framställning av pellets med fördröjd frisättning |
| NZ260408A (en) * | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| US6207199B1 (en) | 1994-01-27 | 2001-03-27 | The Board Of Regents Of The University Of Oklahoma | Process for making a particulate support matrix for making a rapidly dissolving dosage form |
| US6177104B1 (en) | 1994-01-27 | 2001-01-23 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving dosage form |
| US6066337A (en) * | 1994-01-27 | 2000-05-23 | The Board Of Regents Of The University Of Oklahoma And Janssen Pharmaceutica, Inc. | Method for producing a rapidly dissolving dosage form |
| US6187337B1 (en) | 1994-01-27 | 2001-02-13 | The Board Of Regents Of The University Of Oklahoma | Rapidly dissolving dosage form |
| US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
| US5635210A (en) * | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
| US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| DE10300325A1 (de) * | 2003-01-09 | 2004-07-22 | Hexal Ag | Granulat mit öliger Substanz, Herstellungsverfahren und Tablette |
| US6992772B2 (en) * | 2003-06-19 | 2006-01-31 | Optix Lp | Method and apparatus for optical sampling to reduce interfering variances |
| WO2005000237A2 (en) * | 2003-06-25 | 2005-01-06 | University Of Tennessee Research Foundation | Granules containing biologically active substances |
| US20070082027A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for reducing food intake and controlling weight |
| US20070082029A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
| US10647045B1 (en) * | 2016-11-03 | 2020-05-12 | Specialty Earth Sciences, Llc | Shaped or sized encapsulated reactant and method of making |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| US2875130A (en) * | 1956-11-20 | 1959-02-24 | Smith Kline French Lab | Method of preparing sustained release particles and the product of the method |
| US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
| US3062720A (en) * | 1959-05-20 | 1962-11-06 | Philips Roxane | Sustained release pharmaceutical tablet |
| US3146167A (en) * | 1961-10-05 | 1964-08-25 | Smith Kline French Lab | Method of preparing sustained release pellets and products thereof |
| US3400197A (en) * | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| US3629393A (en) * | 1969-09-11 | 1971-12-21 | Nikken Chemicals Co Ltd | Release-sustaining-tablet |
-
1973
- 1973-12-06 DE DE19732360796 patent/DE2360796B2/de not_active Ceased
-
1974
- 1974-01-01 AR AR253732A patent/AR204629A1/es active
- 1974-02-18 BE BE141040A patent/BE811175A/xx unknown
- 1974-03-04 ES ES423856A patent/ES423856A1/es not_active Expired
- 1974-03-14 GB GB1148774A patent/GB1427677A/en not_active Expired
- 1974-04-19 FR FR7413730A patent/FR2253508B1/fr not_active Expired
- 1974-05-29 NL NL7407233A patent/NL7407233A/xx not_active Application Discontinuation
- 1974-06-06 DK DK303974A patent/DK137310C/da active
- 1974-06-07 SE SE7407537A patent/SE7407537L/xx unknown
- 1974-08-28 JP JP49098842A patent/JPS5089521A/ja active Pending
- 1974-10-02 US US05/511,174 patent/US4013784A/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013106998A1 (de) * | 2013-07-03 | 2015-01-08 | Thyssenkrupp Industrial Solutions Ag | Verfahren sowie eine Vorrichtung zur Herstellung einer Tablette |
| US10067039B2 (en) | 2013-07-03 | 2018-09-04 | Thyssenkrupp Industrial Solutions Ag | Method and apparatus for producing a pellet |
Also Published As
| Publication number | Publication date |
|---|---|
| DK303974A (OSRAM) | 1975-07-28 |
| FR2253508B1 (OSRAM) | 1977-11-10 |
| BE811175A (fr) | 1974-06-17 |
| NL7407233A (nl) | 1975-06-10 |
| ES423856A1 (es) | 1976-05-01 |
| AR204629A1 (es) | 1976-02-20 |
| SE7407537L (OSRAM) | 1975-06-09 |
| GB1427677A (en) | 1976-03-10 |
| DK137310C (da) | 1978-07-24 |
| US4013784A (en) | 1977-03-22 |
| DK137310B (da) | 1978-02-20 |
| DE2360796A1 (de) | 1975-06-12 |
| FR2253508A1 (OSRAM) | 1975-07-04 |
| JPS5089521A (OSRAM) | 1975-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2360796B2 (de) | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm | |
| DE69123075T2 (de) | Ueberzogene Zusammensetzung sowie Verfahren zu ihrer Herstellung | |
| DE69231499T2 (de) | Zusammensetzung auf der basis von mikrokristalliner zellulose für die herstellung von kugelförmigen teilchen | |
| DE69118533T2 (de) | Verfahren zur herstellung poröser zellulosenmatrizen | |
| DE69531957T2 (de) | Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung | |
| DE3586600T2 (de) | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. | |
| DE3877764T2 (de) | Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren. | |
| DE69530973T2 (de) | Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen | |
| DE69535445T2 (de) | Schmelzextrudierte oral verabreichbare Opioidformulierungen | |
| DE69311800T2 (de) | Verfahren zur herstellung von pellets mit verzögerter freisetzung | |
| EP0181515B1 (de) | Verfahren zur Herstellung einer wässrigen Überzugsmitteldispersion und ihre Verwendung zum Überziehen von Arzneimitteln | |
| DE3685927T2 (de) | Vitamine enthaltende granule. | |
| DE69936430T2 (de) | Verfahren zur Herstellung von in der Mundhöhle rasch zerfallenden Tabletten | |
| DE69233130T2 (de) | Kaubare zusammensetzung zur arzneimittelfreisetzung | |
| DE69128569T2 (de) | Tablette mit verzögerter Wirkstoffabgabe | |
| DE69104539T4 (de) | Granulare Zubereitungen und Verfahren zur ihrer Herstellung. | |
| DE4031881C2 (de) | Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung | |
| DE69625813T2 (de) | Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast | |
| DE69207799T2 (de) | Pharmazeutische Zubereitung mit verzögerter Wirkstoffreigabe und Verfahren zur Herstellung derselben | |
| EP0582186A1 (de) | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung | |
| DE202004003404U1 (de) | Pharmazeutische Zusammensetzung zur kontrollierten Freisetzung von Wirkstoffen | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE2057239C3 (de) | Verfahren zur Herstellung eines stabilen Antischaummittel | |
| DE69712100T2 (de) | Valproinsäure enthaltende mikrosphären für orale verabreichung | |
| DE69008107T2 (de) | Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BHV | Refusal |